- Home
- ASND vs BEN Comparison
ASND vs BEN Comparison
Compare ASND & BEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASND
- BEN
- Stock Information
- Founded
- ASND 2006
- BEN 1947
- Country
- ASND Denmark
- BEN United States
- Employees
- ASND N/A
- BEN N/A
- Industry
- ASND Biotechnology: Pharmaceutical Preparations
- BEN Investment Managers
- Sector
- ASND Health Care
- BEN Finance
- Exchange
- ASND Nasdaq
- BEN Nasdaq
- Market Cap
- ASND 8.4B
- BEN 10.0B
- IPO Year
- ASND 2015
- BEN N/A
- Fundamental
- Price
- ASND $128.13
- BEN $19.57
- Analyst Decision
- ASND Strong Buy
- BEN Sell
- Analyst Count
- ASND 14
- BEN 11
- Target Price
- ASND $192.07
- BEN $20.11
- AVG Volume (30 Days)
- ASND 374.2K
- BEN 4.0M
- Earning Date
- ASND 02-05-2025
- BEN 01-31-2025
- Dividend Yield
- ASND N/A
- BEN 6.54%
- EPS Growth
- ASND N/A
- BEN N/A
- EPS
- ASND N/A
- BEN 0.85
- Revenue
- ASND $365,187,374.00
- BEN $8,478,000,000.00
- Revenue This Year
- ASND $9.76
- BEN N/A
- Revenue Next Year
- ASND $81.02
- BEN $3.68
- P/E Ratio
- ASND N/A
- BEN $23.06
- Revenue Growth
- ASND 115.54
- BEN 8.01
- 52 Week Low
- ASND $111.09
- BEN $18.83
- 52 Week High
- ASND $161.00
- BEN $28.61
- Technical
- Relative Strength Index (RSI)
- ASND 41.36
- BEN 40.14
- Support Level
- ASND $126.38
- BEN $19.28
- Resistance Level
- ASND $137.54
- BEN $19.98
- Average True Range (ATR)
- ASND 5.53
- BEN 0.51
- MACD
- ASND -1.14
- BEN -0.03
- Stochastic Oscillator
- ASND 11.21
- BEN 33.56
About ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
About BEN Franklin Resources Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of October 2024, Franklin had $1.631 trillion in managed assets, composed primarily of equity (38%), fixed-income (32%), multi-asset/balanced (11%) funds, alternatives (15%) and money market funds (4%). Distribution tends to be weighted equally between retail investors (53% of AUM) and institutional accounts (45%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the us-based asset managers we cover, with 30% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.